Last reviewed · How we verify
rhGH injection
Recombinant human growth hormone (rhGH) binds to growth hormone receptors to stimulate growth, metabolism, and protein synthesis.
Recombinant human growth hormone (rhGH) binds to growth hormone receptors to stimulate growth, metabolism, and protein synthesis. Used for Growth hormone deficiency in children, Growth hormone deficiency in adults, Short stature due to growth hormone insufficiency.
At a glance
| Generic name | rhGH injection |
|---|---|
| Also known as | rhGH, daily growth hormone, recombinant growth hormone therapy |
| Sponsor | Changchun GeneScience Pharmaceutical Co., Ltd. |
| Drug class | Growth hormone |
| Target | Growth hormone receptor (GHR) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology |
| Phase | FDA-approved |
Mechanism of action
rhGH is a recombinant form of endogenous human growth hormone that activates growth hormone receptors on target tissues, promoting linear growth in children, increasing lean body mass, reducing fat mass, and enhancing metabolic function. It stimulates insulin-like growth factor 1 (IGF-1) production, which mediates many of its anabolic and growth-promoting effects.
Approved indications
- Growth hormone deficiency in children
- Growth hormone deficiency in adults
- Short stature due to growth hormone insufficiency
Common side effects
- Injection site reactions
- Headache
- Hyperglycemia
- Arthralgia
- Carpal tunnel syndrome
- Fluid retention
Key clinical trials
- ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly (PHASE2)
- Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study) (PHASE2)
- Effects of Recombinant Human Growth Hormone in Elderly Patients With Moderate to Severe Acute Brain Injury (GH-ABI-RCT) (PHASE4)
- Recombinant Human Growth Hormone (rHGH) for Knee Osteoarthritis (KORR) (PHASE1, PHASE2)
- A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature (PHASE2)
- The Efficacy and Safety of Inpegsomatropin Injection in Children With Idiopathic Short Stature (PHASE3)
- Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders (PHASE3)
- A Study of GenSci134 in Children With Growth Hormone Deficiency (PGHD) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- rhGH injection CI brief — competitive landscape report
- rhGH injection updates RSS · CI watch RSS
- Changchun GeneScience Pharmaceutical Co., Ltd. portfolio CI